Liv 52 was banned in the USA primarily because a comprehensive study indicated it was ineffective in improving liver-related outcomes and, more critically, was associated with increased mortality in a specific vulnerable patient group.
Critical Research Findings Leading to the Ban
A significant study played a pivotal role in the decision to ban Liv 52 across the United States. This research meticulously evaluated the efficacy and safety of the supplement in patients with liver conditions.
Key findings from the study included:
- No Improvement in Outcomes: The research demonstrated that Liv 52 did not improve liver-related events or overall survival rates in treated patients. This indicated a lack of clinical benefit.
- Increased Mortality Risk: Alarmingly, the use of Liv 52 in patients suffering from Child C cirrhosis was directly linked to an increase in mortality. Child C cirrhosis represents the most severe stage of liver disease, where liver function is significantly impaired. For more details on studies related to complementary and alternative medicine and drug-induced liver injury, you can refer to relevant research in this area.
These concerning findings, particularly the heightened risk of death in severely ill patients, led to the nationwide prohibition of Liv 52 in the USA to protect public health.
Global Perspective
Despite its ban in the United States due to safety and efficacy concerns, Liv 52 remains heavily utilized among patients in some Asian countries. This highlights a divergence in regulatory approaches and public health perspectives on herbal and alternative medicines across different regions.
